Slow acceptance of biotreatment systems, perhaps due to limited regulatory pressures, has prompted Celgene Corp. to de-emphasize that line of business and increase its efforts on its chiral chemical business and immune therapeutics.
Last week CELG announced that a bioremediation alliance with Betz Laboratories Inc., reached last January with an optional four-year extension, will be concluded at the end of its first year